SBRT in China: Treatment Planning, Safety and Follow-Up

Understand SBRT eligibility, motion management, image guidance, organ limits, quality assurance and follow-up before stereotactic body radiotherapy.

Key takeaways

SBRT is high-precision external-beam radiation for selected targets outside the brain. The course is short, but each fraction carries a comparatively high dose, so prepare for it as a serious treatment.
Whether SBRT fits a patient comes down to the target's size, location and motion, the organs nearby, any prior radiation and the role SBRT plays in the whole cancer plan. Which brand of machine a hospital owns is secondary.
Simulation, immobilisation, motion management, image guidance and physics checks all count as part of treatment. Expect the planning visit to come well before the first actual radiation fraction.
A central lung lesion beside the main airways, or a target close to bowel, stomach, spinal cord or another sensitive structure, may call for more fractions, a different dose or a different treatment altogether.
Scans after SBRT can show treatment-related change. A team familiar with the treated field should review follow-up imaging; one scan on its own is a weak basis for declaring recurrence.

Full guide

SBRT, also called stereotactic ablative body radiotherapy (SABR), is external-beam radiation that uses precise positioning and focused dose delivery to treat tumours in the body outside the brain.[1] Chinese terminology standards describe stereotactic radiotherapy as using dedicated positioning and localisation to focus a small field, with SBRT as the extracranial form.[2] When the target is in the brain, the usual names are stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy, and neither involves an actual surgical incision.

The appeal is obvious: suitable patients can finish in a handful of fractions instead of several weeks. The catch is that each visit then delivers a higher dose and leaves less room for geometric error. Calling it conventional radiation sped up would be wrong.

The first decision is whether SBRT belongs in this cancer plan

Start by asking the radiation oncologist what job SBRT is doing in this plan:

definitive local treatment of an early, localised tumour;
local treatment where surgery is unsuitable or the patient has declined it;
control of a limited metastatic or recurrent site within a broader plan;
consolidation after systemic treatment;
re-irradiation of a previously treated area; or
symptom control where a stereotactic course offers a specific advantage.

Each of these purposes points to a different dose, fraction count, expected benefit and level of acceptable risk. A spot that is technically treatable can still be the wrong target for now. Active disease elsewhere, an uncertain diagnosis or a systemic-treatment priority can all change the order.

NCI describes SBRT as an option for small, isolated tumours outside the brain and spinal cord, often in the lung or liver, including patients who cannot have surgery because of health, age or tumour location.[3] That does not mean every small lesion should get SBRT. Where surgery, ablation, conventional radiation, systemic therapy or observation would also be reasonable, ask the multidisciplinary team to compare outcomes, whether tissue diagnosis is needed, recovery, side effects and what each option keeps open for later.

Location matters as much as size

You cannot judge a plan from the prescription alone. The same dose and fraction count can be acceptable for a peripheral target yet unsafe next to a major airway, the oesophagus, a bowel loop, stomach, duodenum, spinal cord, brachial plexus, chest wall, kidney or liver remnant.

For lung tumours, “central” and “ultracentral” describe risk. They are not marketing labels. NCI's professional summary notes that three-fraction SBRT is contraindicated for central early-stage non-small-cell lung cancer, based on earlier safety data, and that longer, risk-adapted schedules have been studied instead.[4] This lung-specific example does not transfer directly to other organs, but it shows why “five treatments versus three” is a meaningless comparison without the anatomy and organ dose constraints.

Before you accept a plan, get plain-language answers to four questions:

What exactly is the target, and how certain is its boundary?
Which nearby organ limits the dose?
How does movement change the target's position?
What would make the team add fractions, lower the dose or pick a different method?

Previous radiation raises the stakes and needs its own review. Hand over the earlier DICOM-RT plan, dose, structure set and treatment summary whenever you can. A line saying “radiation to the chest” tells the new team nothing about the cumulative dose to the spinal cord, airway, lung or oesophagus.

Simulation is a rehearsal with measurements

The planning appointment sets up a body position the team can reproduce at every fraction. That may involve a shaped cushion, a vacuum bag, abdominal compression, an arm support or other immobilisation devices. The team then acquires a planning CT and may fuse in diagnostic CT, MRI or PET information where appropriate.

Targets in the lung, liver, pancreas and upper abdomen move with breathing. Depending on the case and the equipment, the answer may be four-dimensional CT, breath-hold, respiratory gating, abdominal compression or real-time tracking. Some workflows rely on implanted fiducial markers and some manage without. Markers are not automatically needed, and placing one carries its own procedural risks.

If possible, the patient should practise the required breathing instructions before travelling. A person who cannot lie flat, keep the arms raised, tolerate immobilisation or reproduce a breath-hold may need a different motion strategy. Sedation is no casual fix, since it affects the breathing pattern and safe transport as well.

After simulation, the radiation oncologist outlines the target volumes and organs at risk, and dosimetrists and medical physicists build and check the plan. This can take days. Wait for a confirmed start date before booking the return flight; radiation rarely begins right after the CT.

Precision is a process, not a machine brand

Several different platforms can deliver SBRT well. Robotic arm, conventional linear accelerator, ring gantry—none of these labels answers the questions that actually matter:

Is the team trained and credentialed for this disease site and this technique?
How is the machine's small-field accuracy checked?
Is patient-specific plan verification performed for every plan?
What imaging is taken before each fraction, and is the position corrected online?
How is motion monitored during delivery?
Who decides when anatomy has changed too much to treat that day?

China's WS 582—2017 standard sets out quality-control tests for X- and gamma-ray stereotactic systems, covering localisation and radiation-field accuracy.[5] The national radiotherapy protection standard goes further, requiring a quality-assurance programme that covers immobilisation, localisation, plan design, dose delivery, verification, identity and site checks, calibration, record keeping and correction of deviations.[6] ASTRO's safety white paper makes the same point from the US side: SRS/SBRT is a resource-intensive, team-based technique that needs trained personnel and a comprehensive quality-assurance programme.[7]

On treatment days, staff reproduce the planned position and take image guidance—usually cone-beam CT or another volumetric or planar image—to align the target or its surrogates. If the patient moves or a session runs long, they may pause and image again. A fraction delayed for re-planning or equipment quality assurance can feel frustrating, but rescheduling is often the safer call.

A short course can have early and late effects

Side effects track the irradiated organ and the dose. Lung SBRT can bring fatigue, cough, chest-wall discomfort, rib injury or radiation pneumonitis. Liver treatment can affect the nearby stomach and bowel or liver function. Spine treatment demands particular attention to the cord and vertebrae. Prostate schedules carry urinary, bowel and sexual effects. Any such list is incomplete, and risks differ sharply by target.

Ask the team to spell out:

common short-term effects and how to manage them at home;
which symptoms warrant a same-day call;
urgent symptoms such as severe breathlessness, chest pain, new weakness, loss of bladder or bowel control, bleeding or rapid deterioration;
possible late effects and how long they will be watched.

Patients sometimes worry about this, so it is worth stating plainly: SBRT does not make you radioactive. The beams come from outside the body and stop when the machine is off.[3]

Follow-up imaging needs the treatment map

The first scan after treatment is not a simple pass or fail. Inflammation, scarring, temporary enlargement or changing contrast uptake can all show up in the treated region, and the timing and appearance depend on the organ and the imaging modality. At the same time, a new opacity is not automatically harmless radiation change either.

Sort out the follow-up before leaving China: the date and type of imaging, who compares it with the simulation and prior diagnostic studies, what triggers a multidisciplinary review, and how a suspected recurrence would be confirmed. If care moves back home, give the receiving team the treatment summary and, where available, the plan and dose data. A single scan read without the treatment field can produce false reassurance or a premature call of progression.

The completion record should list the diagnosis and intent, treated site, simulation date, technique, prescription, delivered dose, dose per fraction, number and dates of fractions, any interruptions, the motion-management method, implanted markers, relevant toxicity and the follow-up plan.

Compare the whole episode, not a per-fraction price

Ask for an estimate that itemises specialist review, repeat imaging or pathology, simulation, contrast, immobilisation, fiducial placement if needed, planning, physics quality assurance, image guidance, every fraction, on-treatment review and follow-up. Also ask what happens to the bill if the target proves unsuitable after simulation, if replanning is needed, or if a fraction is cancelled because anatomy or equipment checks fail.

Build the travel dates around planning time and a clinical review after the last fraction. Some site-specific complications only appear after the patient has boarded the plane, so a named radiation oncologist at home and an emergency plan are still necessary.

Medical disclaimer: This guide is general education and cannot determine whether SBRT is appropriate for a particular patient, or at what dose and fractionation. Those decisions belong to a radiation oncologist and a qualified physics team working from the patient's complete pathology, imaging, prior treatment and organ-at-risk constraints. Severe or rapidly worsening symptoms need urgent local assessment.

Related guides

Radiation therapy in China
Transferring DICOM and prior radiotherapy plans
Multidisciplinary cancer care
Follow-up after treatment abroad

FAQ

Is SBRT the same as radiosurgery?

They share the same stereotactic localisation and focused external radiation. SBRT is the term usually used for targets outside the brain; SRS generally means intracranial treatment. Neither involves a surgical incision.[1][2]

Why can two patients with similar-sized tumours receive different numbers of fractions?

Location, motion, nearby sensitive organs, prior radiation and the intent of treatment can each change what schedule is safe. A risk-adapted course may add fractions to stay within organ limits, so a lower visit count is not automatically the better option.[4]

Do all lung or liver targets need implanted fiducial markers?

No. It depends on how visible the target is, the motion-management method and the treatment platform. Ask how the team will localise and track the target, and what extra risk the marker-placement procedure itself would add.

Can one scan after SBRT prove that treatment failed?

Rarely on its own. Treatment-related inflammation and scarring can change the size or appearance of the area. The team should weigh serial imaging against the treated field, the clinical picture and the expected timeline, and investigate further when recurrence is still suspected.

What SBRT records should I take home?

Take home the treatment summary covering site, intent, technique, total and per-fraction dose, dates, motion method, toxicity and follow-up. If any future radiation is on the cards, also ask for the DICOM-RT plan, dose and structure files.